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Abstract
Background: It is not known whether segmentation of an in vitro fertilisation (IVF) cycle, with freezing of all
embryos prior to transfer, increases the chance of a live birth after all embryos are transferred.
Methods: In a prospective study of UK Human Fertilisation and Embryology Authority data, we investigated the
impact of segmentation, compared with initial fresh embryo followed by frozen embryo transfers, on live birth rate
and perinatal outcomes. We used generalised linear models to assess the effect of segmentation in the whole
cohort, with additional analyses within women who had experienced both segmentation and non-segmentation.
We compared rates of live birth, low birthweight (LBW < 2.5 kg), preterm birth (< 37 weeks), macrosomia (> 4 kg),
small for gestational age (SGA < 10th centile), and large for gestational age (LGA > 90th centile) for a given ovarian
stimulation cycle accounting for all embryo transfers.
Results: We assessed 202,968 women undergoing 337,148 ovarian stimulation cycles and 399,896 embryo transfer
procedures. Live birth rates were similar in unadjusted analyses for segmented and non-segmented cycles (rate ratio 1.05,
95% CI 1.02–1.08) but lower in segmented cycles when adjusted for age, cycle number, cause of infertility, and ovarian
response (rate ratio 0.80, 95% CI 0.78–0.83). Segmented cycles were associated with increased risk of macrosomia
(adjusted risk ratio 1.72, 95% CI 1.55–1.92) and LGA (1.51, 1.38–1.66) but lower risk of LBW (0.71, 0.65–0.78) and SGA (0.64,
0.56–0.72). With adjustment for blastocyst/cleavage-stage embryo transfer in those with data on this (329,621 cycles),
results were not notably changed. Similar results were observed comparing segmented to non-segmented within 3261
women who had both and when analyses were repeated excluding multiple embryo cycles and multiple pregnancies.
When analyses were restricted to women with a single embryo transfer, the transfer of a frozen-thawed embryo in a
segmented cycles was no longer associated with a lower risk of LBW (0.97, 0.71–1.33) or SGA (0.84, 0.61–1.15), but the risk
of macrosomia (1.74, 1.39–2.20) and LGA (1.49, 1.20–1.86) persisted. When the analyses for perinatal outcomes were
further restricted to solely frozen embryo transfers, there was no strong statistical evidence for associations.
Conclusions: Widespread application of segmentation and freezing of all embryos to unselected patient populations
may be associated with lower cumulative live birth rates and should be restricted to those with a clinical indication.
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Background
In vitro fertilisation (IVF) commonly involves ovarian
stimulation to produce a number of oocytes, followed by
fertilisation of these oocytes and fresh embryo transfer,
with surplus embryos frozen for transfer in subsequent
menstrual cycles. However, recent advances have led
some to promote stimulation of the ovaries to produce
an excess of oocytes and then freezing all embryos be-
fore transferring them to the woman at a later time
(known as segmentation of the IVF cycle) [1–3]. As cou-
ples undertaking assisted conception wish to maximise
the chance of having a healthy baby, consideration of
whether segmentation will improve the live birth rate
and reduce adverse perinatal outcomes is critical.
The evidence suggesting segmentation may increase
live birth rates is largely based on observational studies,
with limited confounder adjustment, that report rates in
frozen embryo compared with fresh embryo transfers,
rather than explicitly comparing segmentation with non-
segmentation [4–7]. Registry studies have also not con-
sidered that the underlying patient prognosis of women
with fresh and frozen embryos transfers may differ, with
women experiencing a frozen embryo transfer more
likely to have a higher oocyte yield, a larger cohort of
embryos to select from, and a blastocyst transfer. Fur-
thermore, these studies with few exceptions [8, 9] have
not generally reported the live birth rate accounting for
all embryos transferred during an ovarian stimulation
cycle, but primarily focused on maternal and perinatal
outcomes per embryo transfer. They find some evidence
for reduced risk of preterm birth and lower birthweight
with segmentation, but higher risk of hypertensive disor-
ders of pregnancy, large for gestational age (LGA), and
neonatal and infant mortality.
Of 6 randomised trials comparing segmentation to
non-segmentation, 2 were in highly selected clinical
populations, with 1 only including women with poly-
cystic ovarian morphology (131 women) [10], and the
other only including women with polycystic ovarian
syndrome (1508 women) [11]. A third trial only in-
cluded women with an anticipated normal ovarian re-
sponse in analyses (101 of the 411 women initially
randomised) [12]. While these studies suggested a
benefit of segmentation, their select populations may
limit the generalisability of their findings to the ma-
jority of women receiving IVF. A trial with wider in-
clusion criteria and that included all randomised
women in analyses (782 women) did not observe an
improvement in live birth rates or fewer complica-
tions related to ovarian stimulation with segmentation
[13]. Similarly, a larger trial (2157 women) where a
normal response to ovarian stimulation was antici-
pated, there was no improvement in live birth rates
with segmentation of the cycle. A more recent trial of
good prognosis patients (1650 women) using contem-
porary laboratory techniques and blastocyst culture
did observe an improvement if the initial embryo
transfer was frozen [14]. Only 2 of the 6 trials have
examined cumulative live birth rates, and despite
these, initial apparent improvements for the first
transfer have not found a sustained improvement in
cumulative live birth rates between segmented and
non-segmented cycles [11, 14], consistent with a re-
cent observational study [15].
The aim of this study was to determine whether seg-
mentation of the IVF cycle improves the likelihood of a
healthy live birth per IVF cycle initiated.
Methods
Source of data
We analysed an anonymised database provided by the
Human Fertilisation and Embryology Authority (HFEA),
who have a statutory duty to collect data on all in vitro
fertilisation treatment in the UK. By law, clinicians pro-
vide details of patients, their treatment, and its outcome.
The HFEA provided data between 2003 and 2013 inclu-
sive, including linkage of individual embryo transfers to
ovarian stimulation. The HFEA provided ethical ap-
proval for this study.
We excluded all non-IVF treatments (i.e. donor insem-
ination (DI) and gamete/zygote intrafallopian transfer
(GIFT/ZIFT)) as well as treatment involving oocyte do-
nation, embryo donation, preimplantation genetic test-
ing, or surrogacy. Ovarian stimulation for the sole
purpose of storing oocytes was also excluded, as was the
treatment for the sole purpose of research. Cycles where
no oocytes were collected and therefore neither seg-
mented nor non-segmented cycles could take place were
excluded. Due to a lack of data regarding live birth and
perinatal outcomes in those treated in 2013, we also ex-
cluded treatment from this year. Following these
planned exclusions, the analysis cohort included 202,968
women undergoing 337,148 ovarian stimulation cycles
and 399,896 embryo transfer procedures (Fig. 1).
Definitions
A cycle of IVF was defined as a planned ovarian stimula-
tion followed by transfer of all fresh and/or frozen em-
bryos. Live birth was defined as at least one infant born
after 24 weeks of gestation and surviving for 1 month.
Our primary outcome measure was the cumulative live
birth rate within the IVF cycle, defined as the probability
of at least one live birth in a given ovarian stimulation
cycle, i.e. the live birth rate from all fresh embryo and/or
frozen embryo transfers following ovarian stimulation.
We defined a segmented cycle as ovarian stimulation
followed by creation and freezing then thawing of em-
bryos and transfer of frozen embryos only. A non-
Smith et al. BMC Medicine          (2019) 17:202 Page 2 of 13
segmented cycle was defined as ovarian stimulation
followed by creation and immediate transfer of one or
more fresh embryo(s), with possible freezing, thawing,
and transfer of frozen embryos.
Patient age in years, number of oocytes retrieved, and
cause of infertility were reported by clinicians in the
HFEA data. As the HFEA data linked treatment to indi-
vidual women, we were able to ascertain the number,
nature, and outcome of previous IVF cycles.
We defined preterm birth as gestational age less than
37 weeks; we also examined the associations with very
preterm birth (less than 33 weeks). Birthweight was
Fig. 1 Formation of the analysis cohorts
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provided in 100-g increments and categorised as low
birthweight (less than 2.5 kg) and very low birthweight
(less than 1.5 kg). Macrosomia was defined as birth-
weight greater than 4.0 kg. Small for gestational age
(SGA) and LGA were defined as below the 10th and
above the 90th percentile, respectively, of UK sex and
gestational age-standardised reference charts [16]. SGA
and LGA could not be defined for 2025 and 585 live-
births, respectively, because the HFEA combined those
with birthweight less than 1 kg into 1 category to ensure
participant anonymity or because the gestational age was
above the range of the reference charts. For multiple
births, the earliest gestational age and lowest birthweight
(or in the case of macrosomia and large for gestational
age, highest birthweight) were used for categorisation. In
cycles in which more than 1 embryo transfer procedure
resulted in a live birth, only the first live birth was
considered.
Statistical methods
We compared cumulative live birth rates and perinatal
outcomes within segmented and non-segmented cycles
using a rate ratio calculated by a generalised linear
model. To account for women who had more than one
cycle, we calculated confidence intervals using robust
standard errors that allowed for correlation within
women [17]. We considered age at time of ovarian
stimulation, cycle number, number of oocytes retrieved,
cause of infertility, and developmental stage (whether
blastocyst or cleavage-stage embryo was transferred) to
be the potential confounders given their known associa-
tions with cumulative live birth rate within a cycle and
likely influence on couple and clinician’s choice to seg-
ment a cycle [18]. Although in all adjusted models we
used the individual woman’s age, we also considered the
important age thresholds of 35 and 40 years, given the
known monotonic decline in IVF success rates from age
35 and that many funders consider age 40 as a clinical
threshold for the withdrawal of funding. Other potential
confounders that are not in the HFEA dataset (and
therefore not included in our models) are socio-
economic position and associated characteristics such as
body mass index and smoking.
To adjust for observed confounders, we included all
eligible ovarian stimulation cycles and calculated un-
adjusted rate ratios and rate ratios adjusted for age, cycle
number, number of oocytes retrieved, and cause of infer-
tility. In our primary analyses, we did not adjust for the
embryonic developmental stage because of differential
missing data, but we did so in the additional analyses
(see below). Details of how these confounders were cate-
gorised are provided in Additional file 1. Similar analyses
of perinatal outcomes, restricted to those cycles with at
least one live birth, were conducted. For cumulative live
birth rates within cycles, we further calculated the rate
ratios stratified by age categories, both unadjusted and
adjusted for cycle number and the number of oocytes re-
trieved. To exclude the influence of multiple pregnancy
on adverse perinatal outcomes, we repeated the analysis
comparing the segmented and non-segmented cycles for
those women with a singleton live birth, further adjust-
ing by including a binary variable for previous IVF live
birth. Furthermore, as adverse perinatal outcomes are
associated with the number of embryos transferred [19],
we investigated whether the effect of segmentation on
perinatal outcomes could be mitigated by a single em-
bryo transfer, by repeating the analysis restricted to live
births following single embryo transfer. To assess
whether our results were sensitive to changes over time
in live birth rates, clinical practices, and embryo freezing
technology, we repeated our analysis restricted to cycles
initiated from 2011 onwards to cover the time period
when vitrification of embryos was increasingly being
adopted by IVF laboratories as the standard practice
[20]. We also repeated our analyses restricted to the first
embryo transfer in each cycle (i.e. the fresh embryo
transfer in a non-segmented cycle and the first frozen
embryo transfer in a segmented cycle) in order to exam-
ine the effect of segmentation on the transfer of the best
quality embryo(s). We further repeated our analyses ex-
cluding live births after fresh embryo transfer, in order
to examine the effect of segmentation on perinatal out-
comes following frozen embryo transfer.
Blastocysts (as compared to cleavage-stage embryos)
may be more likely to survive freezing (and hence be
available for transfer), and this could influence clinician
choices in relation to segmentation. There is also evi-
dence that live birth rates are higher in cycles where
blastocysts have been transferred [21]. Hence, develop-
mental stage at freezing could confound the associations
we have examined. Information on the developmental
stage at freezing is not provided in the HFEA data, but
the stage at transfer is provided. This information was
differentially missing, with missing data on 37% of the
segmented cycles and 1% of the non-segmented cycles
(Table 1). As a result, we did not adjust for this variable
in our main analyses. In additional complete case ana-
lyses, we did control for it in the association with live
birth in those cycles with data on the developmental
stage at transfer (5319 segmented and 324,302 non-
segmented cycles) [22].
In a second analysis, we attempted to adjust for both
measured and unmeasured confounders by undertaking
analyses within women who had undergone more than
one treatment cycle and on whom at least one of the re-
peat cycles was segmented and one non-segmented.
These analyses control for unmeasured confounders that
do not change, or change relatively little (in comparison
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with differences between women), as women have repeat
treatments. In these analyses, we assumed there was
control for socio-economic position and reason for seek-
ing IVF treatment, as these are likely to remain the same
as a woman has repeat cycles, and that there was also
some control for characteristics such as body mass index
and smoking, which may change between treatment cy-
cles within women, but are likely to be more similar
within women across cycles than between different
women. These analyses would be less likely to control
for some factors that influence the choice of treatment,
such as developmental stage, which may change between
cycles. While this within-women analysis can better ad-
just for unmeasured confounders, it can introduce bias if
the decision to switch strategies (change from segmenta-
tion to non-segmentation of the cycle or vice versa) is
related to successful live birth. To deal with this in later
cycles, we adjusted the rate ratios by including binary
variables in the generalised linear models that recorded
whether the woman had previously had a segmented
cycle, whether she had a successful live birth in a previ-
ous cycle, and whether it was her last cycle. These ad-
justed rate ratios were stratified by the cycle number,
restricted to no more than the third cycle to maintain at
least 500 observations in each stratum.
There was a small amount of missing information on
gestational age (0.6%), birthweight (2.3%), large for ges-
tational age (3.4%), and SGA (4.2%); we undertook ana-
lyses for these outcomes on those with complete data
(i.e. the vast majority of the cohort).
Results
Analysis 1: Between women including all eligible cycles
Of the 337,148 eligible cycles, 8393 (2.5%) were seg-
mented (Table 1). Segmented cycles were more frequent
in younger women, in first cycles, when more than 15
oocytes were retrieved, when the cause of infertility was
ovulatory, and for blastocyst-stage embryos (Table 1).
The unadjusted cumulative live birth rate within a cycle
was slightly higher in segmented compared with non-
segmented cycles (Fig. 2). However, in adjusted analyses,
cumulative live birth rates within a cycle were lower in
segmented cycles for all age groups and oocyte yields
(Fig. 2).
Multiple birth, low and very low birthweight, and SGA
were less prevalent, and macrosomia and LGA were
more prevalent, in segmented compared with non-
segmented cycles (Fig. 3). These differences persisted
after adjusting for age, cycle number, and oocytes re-
trieved. The different severities of preterm birth were
Table 1 Details of the analysis cohort of 337,148 cycles of IVF from 202,968 women
Number of cycles Whole cohort, 337,148 Segmented cycles, 8393 (2.5%) Non-segmented cycles, 328,755 (97.5%)
Patient age
Less than 35 years 148,998 (44.2%) 5247 (62.5%) 143,751 (43.7%)
35–39 years 134,931 (40.0%) 2530 (30.1%) 132,401 (40.3%)
More than 39 years 53,219 (15.8%) 616 (7.3%) 52,603 (16.0%)
Cause of infertility (may be none or more than one)
Male factor 142,982 (42.4%) 3402 (40.5%) 139,580 (42.5%)
Tubal 61,527 (18.2%) 1557 (18.6%) 59,970 (18.2%)
Ovulatory 40,696 (12.1%) 1814 (21.6%) 38,882 (11.8%)
Endometriosis 21,333 (6.3%) 448 (5.3%) 20,885 (6.4%)
Cycle number
First cycle 173,776 (51.5%) 5625 (67.0%) 168,151 (51.1%)
Later cycle 163,372 (48.5%) 2768 (33.0%) 160,604 (48.9%)
Oocytes collected
1–3 31,291 (9.3%) 172 (2.0%) 31,119 (9.5%)
4–9 141,837 (42.1%) 936 (11.2%) 140,901 (42.9%)
10–15 103,820 (30.8%) 1351 (16.1%) 102,469 (31.2%)
16+ 60,200 (17.9%) 5934 (70.7%) 54,266 (16.5%)
Stage of the embryo at first transfer (% non-missing)
Cleavage 270,919 (82.2%) 3742 (70.4%) 267,177 (82.4%)
Blastocyst 58,702 (17.8%) 1577 (29.6%) 57,125 (17.6%)
Missing (% all cycles) 7527 (2.2%) 3074 (36.7%) 4453 (1.4%)
At least one live birth following ovarian stimulation 105,174 (31.2%) 2748 (32.7%) 102,426 (31.2%)
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similar in segmented and non-segmented cycles
(Fig. 3). Similar results but with wider confidence in-
tervals were observed when the analysis was restricted
to the 82,561 singleton live births (Additional file 1:
Figure S1). However, when the analysis was restricted
to live births following single embryo transfer, there
was no strong statistical evidence for the associations
with low birthweight and SGA, but the increased
prevalence of macrosomia and LGA with segmented
cycles persisted (Additional file 1: Figure S2). When the
analyses were repeated restricted to the most recent years
of treatment (i.e. those from 2011 to 2013), the results
were similar to those in the main analyses with all years of
treatment included, but with wider confidence intervals
(Additional file 1: Figure S3 and S4). When the analyses
were stratified by stage of embryo development at transfer,
the results were similar (Additional file 1: Figure S5).
When just the first embryo transfer in each cycle was con-
sidered, the unadjusted and adjusted live birth rates were
lower for segmented cycles (Additional file 1: Figure S6), and
the results for perinatal outcomes were similar to the main
analysis (Additional file 1: Figure S7). When the analyses for
perinatal outcomes were restricted to frozen embryo trans-
fers, the sample size was restricted to 10,928 cycles, and there
was no strong statistical evidence for associations (Add-
itional file 1: Figure S8).
Of the 5645 segmented cycles that did not result in a
live birth, 3657 (64.8%) used all stored embryos before
commencing a new cycle or the end of the study period.
Embryo storage took place in 95,477 (29.0%) of non-
segmented cycles. Of the 49,975 non-segmented cycles
with embryo storage that did not result in a live birth,
23,385 (46.8%) used all stored embryos before commen-
cing a new cycle or the end of the study period.
Analysis 2: Within women who had both segmented and
non-segmented cycles
There were 3221 women who had both segmented
and non-segmented cycles (Fig. 1). In these women,
the cumulative live birth rate within a cycle was lower
in segmented cycles than in non-segmented cycles.
However, this difference may be biassed by the asso-
ciation of switching between treatments and the rela-
tionship of this to live birth. Furthermore, there were
only 260 (8.0%) live births in the first cycle, reflecting
the fact that restricting to women who had more than
1 cycle excludes women who had a live birth in their
first cycle and then discontinued treatment. When we
restricted analyses to the second and third cycles,
with adjustment for previous segmentation, previous
live birth, and whether it was the last cycle, evidence
for lower live birth rates with segmented compared to
non-segmented cycles remained, though the relatively
small sample sizes means these results are less pre-
cisely estimated (wider confidence intervals) than the
analyses presented above in all women (Table 2). We
were unable to examine the perinatal outcomes due
to the small number (155) of women who had both a
Fig. 2 Live birth rate ratios for segmented cycles compared with non-segmented cycles, in 202,968 women undergoing 337,148 cycles of IVF.
*Adjusted for age (where not stratified), cycle number, cause of infertility, and oocytes retrieved (where not stratified)
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live birth from a segmented cycle and a live birth
from a non-segmented cycle.
Discussion
In this large population cohort, we demonstrate that seg-
mentation of the IVF cycle (i.e. freezing all embryos ra-
ther than performing an initial fresh embryo transfer
and subsequent frozen embryo transfers if unsuccessful)
is associated with a lower cumulative live birth rate from
all embryo transfers. We showed this in a between-
women analysis, with a large cohort, after adjusting for
age, cycle number, and number of oocytes retrieved after
ovarian stimulation. Furthermore, we observed the same
lower live birth rates in segmented cycles in a within-
women analysis, which controls for potential confound-
ing by measured and unmeasured characteristics that do
not change much between repeated cycles. Notably, this
potentially detrimental effect of segmentation on cumu-
lative live birth rates was only observed in the multivari-
able analyses. In the unadjusted analyses, the live birth
rate was higher for segmented cycles, in accordance with
previous registry data examining the outcome of a single
fresh or frozen embryo transfer. Segmented cycles were
associated with an increased risk of macrosomia and a
large-for-gestational-age infant in both analyses, with
these findings persisting when analyses were restricted
to singleton live births and also to live births following
single embryo transfer. Our findings are important for
infertile couples undergoing IVF, clinicians, and policy-
makers, as they suggest that the increasing promotion of
segmented treatment cycles [3] may be premature and
unlikely to deliver what is being promised with regard to
both increasing the likelihood of live birth and reducing
the adverse perinatal outcomes.
Our analyses examined the cumulative live birth rate
within an IVF cycle, incorporating all embryo transfers
rather than just the first, which is the key outcome of
interest to infertile couples. Most previous studies have
only compared the transfer of fresh or frozen embryos
and extrapolated their results to support segmentation
[4, 10–13]. A single observational study (14,331 women)
concluded that cumulative live birth rates were similar
to fresh transfer among high responders but were detri-
mental in normal and suboptimal responders as defined
by oocyte yield of 10–15 and < 10, respectively [9]. The
largest RCT to date (1508 women), which did compare
cumulative live birth rate within an IVF cycle, did not
find an improvement in cumulative live birth rates [11],
Fig. 3 Risk ratios of perinatal outcomes following first live birth within a cycle, for segmented cycles compared with non-segmented cycles, in
105,174 live births from 202,968 women undergoing 337,148 cycles of IVF. *Adjusted for age, cycle number, cause of infertility, and oocytes
retrieved. †Information is non-missing
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with the other two large RCTs similarly not showing a
benefit if the initial embryo transfer was frozen as com-
pared to a fresh transfer or a reduced time to pregnancy
with segmentation [13, 23]. Specifically, Chen and col-
leagues reported a cumulative live birth rate of 62.3% for
the initial frozen embryo transfer and 59.7% for the fresh
embryo group (rate ratio 1.04, 95% CI 0.96 to 1.13) [11],
with the subsequent trial in women without PCOS the
live birth rates for the initial frozen embryo group and
the fresh embryo group of 48.7% and 50.2%, respectively
(rate ratio 0.97, 95% CI 0.89 to 1.06; P = 0.50) [23]. At
12 months of follow-up, Vuong and colleagues reported
a cumulative live birth of 48.8% in the frozen embryo
group and 47.3% in the fresh embryo group (risk ratio
1.03, 95% CI 0.89 to 1.19; P = 0.72) [13].
That there was a negative effect of segmentation in the
adjusted analyses after accounting for the important pa-
tient prognostic criteria of age, number of IVF cycles,
cause of infertility, and ovarian response guide may help
explain our discordance with previous superiority for
frozen embryo transfer when simple fresh versus frozen
analyses of registry data have been undertaken. Younger
women are more likely to have more oocytes retrieved,
develop blastocysts, have spare good-quality embryos
available for freezing, and have euploid embryos. There
would be disproportionate over-representation of any or
all of these characteristics when simply comparing fresh
versus frozen embryo transfers. Even in older women,
those with a better ovarian response and higher oocyte
yield are more likely to have frozen embryos available
for transfer and better quality embryos, such that even
in age-stratified results, frozen embryo groups will con-
tinue to appear to do better. Our observed detrimental
effect for segmentation in unselected women, and also
in our oocyte yield-stratified analysis, may reflect the
partial loss of viable embryos during cryopreservation.
All freezing techniques are associated with the loss of
some embryos, but this adverse effect is known to be
greatest for slow freezing and freezing at the earlier
stages of embryo development. For these clinical prac-
tices which dominated at the time of this study cleavage-
stage survival rates were reported to be 60–91% [24],
with recent improvements in laboratory techniques, our
observed differences may be attenuated. Our results may
also highlight that optimal endometrial preparation re-
gimes have yet to be elucidated [25]. A mixture of nat-
ural and medicated frozen embryo transfer cycles with
variable degrees of luteal support may contribute to the
poorer results with segmentation. Replication of our
analyses in patients solely exposed to extended culture
and blastocyst vitrification will be of interest and help
clarify the generalisability of our findings.
The observed reduced risk of low birthweight and
SGA in segmented cycles is consistent with previous
studies [4, 26]. This was not accompanied by a reduced
risk of prematurity, with similar results when we re-
stricted analyses to singleton births, possibly due to a
detrimental effect of ovarian stimulation on placentation,
which is temporally overcome with segmentation [4].
The biological plausibility for an impact on placentation
is supported by recent observations that both high
oestradiol at the end of ovarian stimulation [27] and
supraphysiological maternal oestradiol during the first
trimester [28] are associated with an increased risk of
SGA. Animal model data suggests that oestrogen critic-
ally regulates trophoblast invasion and exposure to ex-
cessive oestrogen in early gestation impairs spiral artery
invasion—a known determinant of intrauterine growth
Table 2 Comparison of live birth rate in segmented and non-segmented IVF cycles within 3221 women undergoing 8618 cycles of
IVF, who had both segmented and non-segmented cycles
Cycles (% cycles) Live births* (live birth rate) Rate ratio (95% CI) Rate ratio, adjusted† (95% CI)
All cycles
Segmented 3361 (39.0%) 556 (16.5%) 0.70 (0.63, 0.76)
Non-segmented 5357 (61.0%) 1250 (23.8%) 1
First cycle
Segmented 1720 (53.4%) 125 (7.3%) 0.81 (0.64, 1.02)
Non-segmented 1501 (46.6%) 135 (9.0%) 1
Second cycle
Segmented 1150 (35.7%) 313 (27.2%) 0.85 (0.76, 0.95) 0.68 (0.50, 0.92)
Non-segmented 2071 (64.3%) 666 (32.2%) 1 1
Third cycle
Segmented 340 (25.5%) 83 (24.4%) 0.83 (0.67, 1.02) 0.78 (0.59, 1.03)
Non-segmented 994 (74.5%) 294 (29.6%) 1 1
*At least one live birth following ovarian stimulation
†Adjusted for previous segmentation, previous live birth, and whether this was the last cycle
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restriction [29]. Single embryo transfer mitigated the risk
of prematurity and low birthweight in non-segmented
cycles, suggesting that some of the observed detrimental
effects may reflect transfer of a non-viable second em-
bryo [19], with our observations adding weight to the
case for elective single embryo transfer to optimise peri-
natal outcomes [19].
We observed a higher risk of LGA in segmented com-
pared to non-segmented cycles, with an absolute rate of
18% (rather than the expected 10% based on the 90th
percentile threshold definition) when analyses were re-
stricted to singleton live births or single embryo transfer.
Several studies have shown that the children born after
the transfer of frozen embryos are at an increased risk of
macrosomia and large for gestational age [7, 30], with
the most recent analysis of siblings suggesting a causal
contribution of freezing to increased birthweight [31].
The mechanism however remains unclear, with both
epigenetic modifications during freezing and thawing
and the different maternal endocrine and endometrial
environment proposed [31]. We did not observe any dif-
ference in the risk when comparing perinatal outcomes
after frozen embryo transfer only, suggesting that the in-
creased risk of LGA is a result of only frozen embryo
transfers taking place in a segmented cycle. Given the
well-established risks of large for gestational age on ob-
stetric and long-term offspring outcomes [32], along
with no strong evidence for increased live birth rates,
this would caution against the widespread adoption of
segmentation.
We appreciate that segmentation as it is currently
understood may not appear to be equivalent to the med-
ically indicated cancelled fresh cycles, which will have
dominated at the time of the study. However, elective
cryopreservation of all embryos was historically princi-
pally undertaken for the prevention of ovarian hyper-
stimulation syndrome (OHSS), which is the same
primary indication for which segmentation would be
considered today [1]. The timing of the decision to seg-
ment the cycle, the ovarian stimulation strategies, and
the mode of triggering final oocyte maturation may have
changed, but the principal outcome of not having a fresh
transfer and all embryos being cryopreserved is identical.
The further development and understanding of the po-
tential advantages, including the concept of the endo-
metrium being hindered by the stimulation [33], was an
attempt to explain why frozen embryo transfers were as-
sociated with better clinical outcomes when registry data
was compared, or as an explanation for the observed dif-
ferences in the initial randomised controlled trials, it was
not the primary reason for considering segmentation of
the cycle.
As we do not have the indication for segmentation, al-
ternative medical indications for fresh cycle cancellation
may have contributed to the observed worse cumulative
cycle outcomes, for example, poor endometrial develop-
ment, which may recur in subsequent cycles. However,
analyses of all endometrial thicknesses for all cycles
undertaken in Canada demonstrated that 99.1% of all
fresh cycles had an endometrial thickness ≥ 6 mm and
96.1% had ≥ 7 mm, suggesting that this is an infrequent
finding and would not be responsible for the effect size
observed [15]. Women with PCOS may be more likely
to over-respond and have a medically indicated seg-
mented cycle and are known to have worse obstetric
outcomes [34]. However, fertilisation rates have been
shown to be equivalent in women with PCOS [35], and
with contemporary laboratory techniques, they may even
be anticipated to have higher cumulative live birth rates
due to their potential for a higher oocyte yield [36]. We
noted that segmented cycles had more embryos created
and more embryos transferred and therefore do not an-
ticipate that our results are due to poorer prognosis pa-
tients in the segmented group. Other indications such as
concerns regarding the adverse effect of progesterone
elevation on the endometrium and embryo quality [37,
38] may also have contributed. However, as progester-
one concentration reflect the ovarian stimulation [39],
this would emphasise the need for clinicians to not dis-
regard optimal gonadotrophin dosing simply because the
OHSS risk can be mitigated.
Our study has a number of strengths: we included over
200,000 women undertaking more than 330,000 IVF cy-
cles and 399,000 embryo transfers. We incorporated all
eligible IVF cycles undertaken in the UK over a 10-year
period. The HFEA is subject to parliamentary jurisdic-
tion and the data source subject to routine quality assur-
ance checks and performs well in terms of completeness
and accuracy [40]. Through a unique maternal identifier,
we linked each woman to every IVF cycle and every em-
bryo transfer they had undertaken, irrespective of
whether the woman had moved clinic. This enabled us
to also identify over 3000 women who had experienced
both segmented and non-segmented cycles, and
complete a within-women analyses, which, consistent
with analyses in all eligible women, showed lower live
birth rates in segmented compared to non-segmented
cycles. We also demonstrated robust findings across a
range of additional analyses.
We acknowledge that our analyses had some limita-
tions. We have utilised population data derived from a
decade of treatment, which will include heterogeneous
clinical and laboratory practices [18, 19, 41, 42]. How-
ever, this heterogeneity reflects contemporary global
clinical practice, with units continuing to differ in freez-
ing protocols, and with a large variation in the technical
skills of embryologists. We did not have the reason for
segmentation of the cycle, but we have adjusted all
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analyses for the underlying cause of infertility, and our
results were largely unchanged. We did not have detailed
information on whether vitrification or slow freezing
was used or the stage of embryo development when
freezing occurred. Information on the developmental
stage at transfer was missing on 37% of the segmented
cycles but just 1% of non-segmented cycles; therefore,
we did not adjust for this in our main analyses. As a re-
sult, our main analyses could be influenced by residual
confounding which would tend to bias the results to-
wards a beneficial effect of segmentation on live birth
rate (given blastocysts may better survive freezing and
be more likely to result in a live birth). This confounding
might therefore mask a stronger association between
non-segmentation and live birth. In additional analyses,
we controlled for cleavage or blastocyst stage in those
participants with data on this. Because of the differential
missingness, these complete case analyses might suffer
from selection bias [22]. However, as long as missingness
in the covariate is unrelated to the outcome, then the
complete case analysis will be unbiassed—even if miss-
ingness is related to the covariate [22]. In support of
this, the results were essentially the same as our main
analyses.
We appreciate that there have been continued im-
provements in vitrification survival rates in recent years
and that with current vitrification techniques, the ob-
served differences may be attenuated. We were unable
to obtain precise dates from clinics regarding the switch
from slow freezing to vitrification as for many systems
ran in parallel depending on which stage of embryo de-
velopment was being frozen. Restricting our analyses to
the most recent 2 years of available data, where there
would be potentially less heterogeneity of practice and
extended culture and vitrification of blastocysts may be
more prevalent, did not lead to any substantial changes
in our results, which further supports our main results
being relevant to contemporary populations. In some
countries, e.g. Germany, slow freezing still dominates
due to legislative reasons, and replication of our results
with contemporaneous data in other settings would be
useful to confirm our conclusions.
Prior to 2009, women were only able to store embryos
for 5 years in the UK, and after 2009, this was extended
to 10 years with further storage possible. Consequently,
we appreciate that not all women had used all their em-
bryos, and this may have underestimated the overall cu-
mulative live birth rate. As the number of women who
had used all their embryos was higher in segmented cy-
cles, it is likely that the overall cumulative live birth rate
was more severely underestimated in non-segmented cy-
cles compared with segmented cycles. Similarly, we are
unable to accurately calculate the full reproductive po-
tential of a single IVF cycle, the “one and done”
approach as it is not clear in this population dataset the
desired number of children [43] or how this may affect
the decision to segment the cycle. For the protection of
anonymity, we do not have the date of births for the off-
spring and are therefore unable to calculate the time to
pregnancy for each of the two strategies, but appreciate
the importance of this outcome for patients. Lastly, des-
pite the HFEA having a legislative and regulatory re-
quirement to collect data, the option to participate in
research with the data was introduced in 2009. We ap-
preciate that we may therefore have incomplete data
capture for the later years of the study, but this would
only have biassed the results if consent for data was not
randomly distributed between segmented and non-
segmented cycles, which is unlikely given that the Con-
sent to Disclosure form is completed prior to commen-
cing ovarian stimulation. The consistency of our findings
when restricted to the last 3 years of cycles only (i.e.
2011–2013) with main analyses also suggests that this
change has not biassed our findings. The other possibil-
ity is collider bias, where an unmeasured variable af-
fected both research participation and the need for
segmentation and a separate unmeasured variable af-
fected both research participation and the outcomes of
interest [44]. Replication of our findings in population
cohorts where there is complete data capture would be
useful in addressing potential bias attributable to un-
known reasons for participation.
We did not have detailed data on some potential con-
founders, such as maternal smoking, body mass index,
and socio-economic position. We did not have detailed
information on embryo quality and acknowledge that if
women with poorer quality embryos were more likely to
freeze all embryos than those with good-quality em-
bryos, this may influence the results and explain why
segmentation was associated with worse outcomes.
However, this is unlikely as freezing is generally re-
stricted to good-quality embryos, and our within-women
analysis reached the same conclusion as our between-
women analysis for live birth success, suggesting that the
effect of unmeasured confounders that are likely to
change little within women is limited. The within-
women analysis, by necessity, was restricted to women
who had more than one ovarian stimulation cycle, and
we were unable to examine the perinatal outcomes due
to the small number (155) of women who had a live
birth from a segmented cycle and a live birth from a
non-segmented cycle. We did not have data on endo-
metrial development; however, large population studies
have suggested that endometrial thicknesses < 6mm af-
fects < 1% of cycles [15]. Lastly, we did not have data on
whether embryos were replaced in a medicated or nat-
ural cycle, with no data on the nature or extent of luteal
support [25].
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We acknowledge that segmentation of the cycle is
beneficial for ovarian hyperstimulation syndrome
(OHSS) prevention, but we were unable to undertake
analyses separately in women with and without a diag-
nosis of OHSS, as information on this diagnosis is not
accurately recorded within the HFEA dataset and the in-
dication for segmentation was not available. However,
this is unlikely to have a major impact on our findings
as the incidence of OHSS is low (1% of cycles) [45], and
inclusion of these women would tend to bias the find-
ings towards a benefit of segmentation in the general
IVF patient population of both those with and without
OHSS. We also appreciate that preimplantation genetic
testing (PGT) of blastocysts will require segmentation of
the cycle. However, PGT has not been universally
adopted, pending the outcome of an international multi-
centre trial (NCT02268786) [46].
Conclusion
Cryopreservation is an essential aspect of assisted con-
ception, and its widespread application has maximised
the safety and efficacy of treatment. Our findings show
that 30 years after the introduction of cryopreservation,
elective freezing of all embryos for all patients if used in
an unselected manner, without heed of laboratory ex-
pertise or the patient profile, may potentially comprom-
ise the cumulative live birth rate within a single IVF
cycle. These findings support restricting segmentation to
patients where there is a clear clinical need, such as the
prevention of ovarian hyperstimulation or preimplanta-
tion genetic testing.
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